National Coverage Analysis (NCA) for Positron Emission Tomography (FDG) for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and Testicular Cancers (CAG-00181N)

Contact(s)

Stuart Caplan

stuart.caplan@cms.hhs.gov

410-786-8564

Documents

Tracking Sheet

Technology Assessment for Positron Emission Testing For Six Cancers (Brain, Cervical, Small Cell Lung, Ovarian, Pancreatic and Testicular)

Proposed Decision Memo

Decision Memo

View Public Comments

NCD for Positron Emission Tomography (PET) Scans (220.6)
NCD for FDG PET for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and Testicular Cancers (220.6.14)
NCD for Positron Emission Tomography (FDG) for Oncologic Conditions (220.6.17)

History of Considerations

Original Consideration for Positron Emission Tomography (FDG) for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and Testicular Cancers (this document)

First reconsideration for Positron Emission Tomography (FDG) for Solid Tumors (CAG-00181R)

Second reconsideration for Positron Emission Tomography (FDG) for Cervical Cancer (CAG-00181R2)

Third reconsideration for Positron Emission Tomography for Initial Treatment Strategy in Solid Tumors and Myeloma (CAG-00181R3)

Fourth reconsideration for Positron Emission Tomography (FDG) for Solid Tumors (CAG-00181R4)

National Coverage Analysis (NCA) for Positron Emission Tomography (FDG) for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and Testicular Cancers (CAG-00181N)

Footer

CMS & HHS Websites

Tools

Helpful Links